Bariatric surgery: What is the effect on type 2 diabetes?

Current Opinion in Investigational Drugs

Volumn 10, Issue 10, 2009, Pages 1078-1084

  Dar, M ^a   Pories, W J ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

cell dysfunction; Bariatric surgery; Biliopancreatic diversion; Glucose stimulated insulin secretion; GSIS; Laparoscopic adjustable gastric banding; Malabsorptive procedure; Restrictive procedure; Roux en Y gastric bypass; RYGB

Indexed keywords

BARIATRIC SURGERY; CALORIC RESTRICTION; CELL FUNCTION; HUMAN; INSULIN RESISTANCE; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT CYCLE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL TUMOR; PATHOGENESIS; REMISSION; REVIEW; ROUX Y ANASTOMOSIS; SKELETAL MUSCLE; STOMACH BYPASS; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; GASTRIC BYPASS; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; OBESITY;

EID: 70349733244     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Diabetes: World Health Organization, Geneva, Switzerland (2008). www.who.int/mediacentre/factsheets/fs312/en
2. Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat HA, deRamon RA, Israel G, Dolezal JM et al: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg (1995) 222(3):339-352.
3. Swanson M, Long S, Smith E, MacDonald K, Dohm L, Frazier N, Caro J, Pories WJ: Early gastric bypass provides better control of NIDDM in the morbidly obese. Obesity Surgery 5(2):208.
4. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: A systematic review and meta-analysis. JAMA (2004) 292(14):1724-1737. (Pubitemid 39346675)
5. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I: Weight and type 2 diabetes after bariatric surgery: Systematic review and meta-analysis. Am J Med (2009) 122(3):248-256.e5.
6. National diabetes fact sheet: General information and national estimates on diabetes in the United States: US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, USA (2008). apps.nccd.cdc.gov/DDTSTRS/ FactSheet.aspx
7. Mechanick JI, Kushner RF, Sugerman HJ, Gonzalez-Campoy JM, Collazo-Clavell ML, Guven S, Spitz AF, Apovian CM, Livingston EH, Brolin R, Sarwer DB et al: American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical Guidelines for Clinical Practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Surg Obes Relat Dis (2008) 4(5 Suppl):S109-S184.
8. Kahn SE: The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia (2003) 46(1):3-19. (Pubitemid 36237741)
9. DeFronzo RA: The triumvirate: B-cell, muscle, liver: A collusion responsible for NIDDM. Diabetes (1988) 37(6):667-687.
10. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR: Slow glucose removal rate and hyperinsulinemia precede the development of type 2 diabetes in the offspring of diabetic patients. Ann Intern Med (1990) 113(12):909-915.
11. Vuppalanchi R, Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 49(1):306-317.
12. Home PD, Pacini G: Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: A critical target for insulinsensitizing agents. Diabetes Obes Metab (2008) 10(9):699-718.
13. Muoio DM, Newgard CB: Obesity-related derangements in metabolic regulation. Annu Rev Biochem (2006) 75:367-401.
14. Hulver MW, Dohm GL: The molecular mechanism linking muscle fat accumulation to insulin resistance. Proc Nutr Soc (2004) 63(2):375-380.
15. Muoio DM, Newgard CB: Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol (2008) 9(3): 193-205.
16. Schmitz-Peiffer C: Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann NY Acad Sci (2002) 967: 146-157. (Pubitemid 34721902)
17. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: Possible role in insulin resistance. Science (2003) 300(5622):1140-1142. (Pubitemid 36583097)
18. Eriksson JW: Metabolic stress in insulin's target cells leads to ROS accumulation - A hypothetical common pathway causing insulin resistance. FEBS Lett (2007) 581(19):3734-3742.
19. Chakraborti S, Chakraborti T: Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: A brief overview. Cell Signal (1998) 10(10):675-683.
20. Anderson, EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW 3rd, Kang L, Rabinovitch PS, Szeto HH, Houmard JA et al: Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest (2009):doi:10.1172/JCI37048.
21. Newgard CB, McGarry JD: Metabolic coupling factors in pancreatic β-cell signal transduction. Annu Rev Biochem (1995) 64:689-719.
22. Anello M, Lupi R, Spampinato D, Piro S, Masini M, Boggi U, Del Prato S, Rabuazzo AM, Purrello F, Marchetti P: Functional and morphological alterations of mitochondria in pancreatic β cells from type 2 diabetic patients. Diabetologia (2005) 48(2): 282-289. (Pubitemid 40543300)
23. Kloppel G, Löhr M, Habich K, Oberholzer M, Heitz PU: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res (1985) 4(2): 110-125.
24. Maclean N, Ogilvie RF: Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes (1955) 4(5):367-376.
25. Saito K, Yaginuma N, Takahashi T: Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and non-diabetic subjects. Tohoku J Exp Med (1979) 129(3): 273-283.
26. Robertson RP: Estimation of β-cell by mass by metabolic tests: Necessary, but how sufficient? Diabetes (2007) 56(10): 2420-2424.
27. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG: The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes (1985) 34(3): 222-234.
28. Pfeifer MA, Halter JB, Porte D Jr: Insulin secretion in diabetes mellitus. Am J Med (1981) 70(3):579-588.
29. Houmard JA, Tanner CJ, Yu C, Cunningham PG, Pories WJ, MacDonald KG, Shulman GI: Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl-CoAs in morbidly obese subjects. Diabetes (2002) 51(10):2959-2963.
30. Gray RE, Tanner CJ, Pories WJ, MacDonald KG, Houmard JA: Effect of weight loss on muscle lipid content in morbidly obese subjects. Am J Physiol Endocrinol Metab (2003) 284(4):E726-E732.
31. Friedman JE, Dohm GL, Leggett-Frazier N, Elton CW, Tapscott EB, Pories WP, Caro JF: Restoration of insulin responsiveness in skeletal muscle of morbidly obese patients after weight loss. J Clin Invest (1992) 89(2):701-705.
32. Pender C, Goldfine ID, Tanner CJ, Pories WJ, MacDonald KG, Havel PJ, Houmard JA, Youngren JF: Muscle insulin receptor concentrations in obese patients post-bariatric surgery: Relationship to hyperinsulinemia. Int J Obes Relat Metab Disord (2004) 28(3):363-369.
33. Gastaldi G, Russell A, Golay A, Giacobino JP, Habicht F, Barthassat V, Muzzin P, Bobbioni-Harsch E: Upregulation of peroxisome proliferator-activated receptor γ coactivator gene (PGC1A) during weight loss is related to insulin sensitivity but not to energy expenditure. Diabetalogia (2007) 50(11): 2348-2355.
34. Thyfault JP, Kraus RM, Hickner RC, Howell AW, Wolfe RR, Dohm GL: Impaired plasma fatty acid oxidation in extremely obese women. Am J Physiol Endocrinol Metab (2004) 287(6):E1076-E1081. (Pubitemid 39491949)
35. Berggren JR, Boyle KE, Chapman WH, Houmard JA: Skeletal muscle lipid oxidation and obesity: Influence of weight loss and exercise. Am J Physiol Endocrinol Metab (2008) 294(4):E726-E732.
36. Bikman BT, Zheng D, Pories WJ, Chapman W, Pender JR, Bowden RC, Reed MA, Cortright RN, Tapscott EB, Houmard JA, Tanner CJ et al: Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab (2008) 93(12):4656-4663. The first study to demonstrate amelioration of a known molecular mechanism of insulin resistance (ie, Ser312 IRS-1 phosphorylation) after RYGB. Although the studies were performed in non-diabetic patients, the results represent a template for future research in diabetic patients undergoing bariatric surgery.
37. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes (2003) 52(5):1098-1103. One of the first studies to demonstrate that absence of insulin secretion as a result of β-cell dysfunction in T2DM could be restored as early as 3 months after RYGB, and remained sustained at 6 and 12 months. Insulin sensitivity was also restored at similar time points. These findings challenged the prevailing dogma suggesting that the decreased insulin secretion in T2DM could never be restored to normal levels.
38. Alvarez GC, Faria EN, Beck M, Girardon DT, Machado AC: Laparoscopic spleen-preserving distal pancreatectomy as treatment for nesidioblastosis after gastric bypass surgery. Obes Surg (2007) 17(4):550-552. (Pubitemid 46850198)
39. Clancy TE, Moore FD Jr, Zinner MJ: Post-gastric bypass hyperinsulinism with nesidioblastosis: Subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg (2006) 10(8):1116-1119.
40. Meier JJ, Butler AE, Galasso R, Butler PC: Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased β-cell turnover. Diabetes Care (2006) 29(7):1554-1559.
41. Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S et al: Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: Evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia (2005) 48(11): 2236-2240. (Pubitemid 41618912)
42. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV: Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med (2005) 353(3):249-254.
43. Goldfine AB, Mun EC, Devine E, Bernier R, Baz-Hecht M, Jones DB, Schneider BE, Holst JJ, Patti ME: Patients with neuroglyceopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab (2007) 92(12):4678-4685.
44. Patriti A, Aisa MC, Annetti C, Sidoni A, Galli F, Ferri I, Gullà N, Donini A: How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and β-cell function in Goto-Kakazaki rats through an enhanced proglucagon gene expression and L-cell number. Surgery (2007) 142(1):74-85. (Pubitemid 47042093)
45. Buchan AM, Pederson RA, Chan CB, Brown JC: The effect of massive small bowel resection (MSBR) and small intestinal bypass in the rat on the enteroinsular axis. Regul Pept (1983) 7(3):221-232. (Pubitemid 14249877)
46. Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E et al: Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med (2009) 361(5):445-454.
47. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: A systematic review and meta-analysis. JAMA (2004) 292(14):1724-1737. Meta-analysis of bariatric surgery with a large number of patients and diverse bariatric procedures considered for analysis. One of the most important conclusions of this study was the superiority of malabsorption over restriction as a strategy for diabetes reversal in bariatric surgery.
48. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G: Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes (2006) 55(7):2025-2031. (Pubitemid 44509976)
49. Mingrone G, Henriksen FL, Greco AV, Krogh LN, Capristo E, Gataldelli A, Castagneto M, Ferrannini E, Gasbarrini G, Beck-Nielsoe H: Triglyceride induced diabetes associated with familial lipoprotein lipase deficiency. Diabetes (1999) 48(6):1258-1263. Describes a case report of two non-obese patients with a genetic defect that led to high triglyceride levels and T2DM. The reversal of both the high triglyceride levels and T2DM after BPD surgery suggested that the malabsorption of fat (rather than weight loss) was critical for the reversal of T2DM in these two patients. This finding may have wider applicability to other patients with T2DM, but requires further investigation.
50. Pories WJ, Albrecht RJ: Etiology of type II diabetes mellitus: Role of the foregut. World J Surg (2001) 25(4):527-531. (Pubitemid 32455209)
51. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like-peptide-1(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab (1993) 76(4):912-917.
52. Laferrère B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB, Olivan B: Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care (2007) 30(7):1709-1716. (Pubitemid 47036341)
53. Rodieux F, Giusti V, D'Alessio DA, Suter M, Tappy L: Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity (2008) 16(2):298-305. (Pubitemid 351271908)
54. Vidal J, Nicolau J, Romero F, Casamitjana R, Momblan D, Conget I, Morinigo R, Lacy AM: Long-term effects of Roux-en-Y gastric bypass surgery on plasma GLP-1 and islet function in morbidly obese subjects. J Clin Endocrinol Metab (2009) 94(3): 884-891.
55. Strader A, Vahl T, Jandacek R, Woods S, D'Alessio D, Seeley R: Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rat. Am J Physiol Endocrinol Metab (2005) 288(2):E447-E453.
56. Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, Donini A: Early improvement of glucose tolerance after ileal transposition in a non-obese type 2 diabetes rat model. Obes Surg (2005) 15(9):1258-1264.
57. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J: The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg (2006) 244(5):741-749. (Pubitemid 44629948)
58. Pacheco D, de Luis DA, Romero A, González Sagrado M, Conde R, Izaola O, Aller R, Delgado A: The effects of duodenal-jejunal exclusion on hormonal regulation of glucose metabolism in Goto-Kakizaki rats. Am J Surg (2007) 194(2):221-224. (Pubitemid 47008973)
59. Ramos AC, Galvão Neto MP, de Souza YM, Galvão M, Murakami AH, Silva AC, Canseco EG, Santamaría R, Zambrano TA: Laparoscopic duodenal-jejunal exclusion in the treatment of type 2 diabetes mellitus in patients with BMI < 30 kg/m2 (LBMI). Obes Surg (2009) 19(3):307-312.
60. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, Exenatide-113 Clinical Study Group: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 27(11):2628-2635. (Pubitemid 39441462)
61. Henry RR, Scheaffer L, Olefsky JM: Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab (1985) 61(5):917-925. (Pubitemid 16218491)
62. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M: Adjustable gastric banding and conventional therapy for type 2 diabetes: A randomized controlled trial. JAMA (2008) 299(3): 316-323. Diabetes of early onset (< 2 years) could be reversed by a less-invasive surgical strategy than gastric bypass, such as gastric banding (ie, restriction). Thus, there may be a time period (< 5 years of diabetes) during which overall nutrient intake (if decreased through restriction) could result in diabetes reversal.
63. Shikora SA, Kim JJ, Tarnoff ME: Nutrition and gastrointestinal complications of bariatric surgery. Nutr Clin Pract (2007) 22(1):29-40. (Pubitemid 46175470)
64. Scopinaro N, Gianetta E, Adami GF, Friedman D, Traverso E, Marinari GM, Cuneo S, Vitale B, Ballari F, Colombini M, Baschieri G et al: Biliopancreatic diversion for obesity at eighteen years. Surgery (1996) 119(3):261-268. (Pubitemid 26082661)
65. Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverso E, Friedman D, Camerini G, Baschieri G, Simonelli A: Biliopancreatic diversion. World J Surg (1998) 22(9):936-946. A single institutional study of surgical experience with BPD. Detailed studies of nutrient absorption and overfeeding performed in patients post-BPD suggested the significant malabsorption of protein and fat, and the persistence of stable weight despite overfeeding. Thus, malabsorptive bariatric procedures may potentially induce permanent nutrient malabsorption of protein and fat that 'protects' the patient from overnutrition and obesity.
66. Bradley EL 3rd, Isaacs JT, Mazo JD, Hersh T, Chey WY: Pathophysiology and significance of malabsorption after Roux-en-Y reconstruction. Surgery (1977) 81(6):684-691.
67. Tacchino RM, Mancini A, Perrelli M, Bianchi A, Giampietro A, Milardi D, Vezzosi C, Sacco E, De Marinis L: Body composition and energy expenditure: Relationship and changes in obese subjects before and after biliopancreatic diversion. Metabolism (2003) 52(5):552-558. (Pubitemid 36896280)